Buy Adipotide Peptide – Advanced Fat-Targeting Research Peptide

Adipotide (FTPP) – Fat-Targeting Pro-Apoptotic Research Peptide

Adipotide, also known as FTPP (Fat-Targeting Pro-Apoptotic Peptide) or HKPao, is a synthetic “hunter-killer” peptide composed of two distinct functional domains . It consists of a homing sequence (CKGGRAKDC) that selectively binds to receptors on the vascular endothelium of white adipose tissue (fat), connected via a glycine-glycine linker to a pro-apoptotic sequence (KLAKLAK)2 composed of D-amino acids . This research-grade peptide was developed as a prototype for a new class of anti-obesity candidates and has been studied in primate models . It is strictly for laboratory investigation and is not intended for human consumption.

Key Factual Details

Mechanism of Action & Research Applications

Targeted Adipose Tissue Disruption: Adipotide selectively targets receptors expressed by vascular endothelial cells supplying white adipose tissue . Upon binding, the peptide is internalized and triggers programmed cell death (apoptosis) in these blood vessels, disrupting the blood supply to fat cells .

Apoptotic Mechanism: The KLAKLAK sequence induces the formation of transient pores in mitochondrial membranes, leading to cytochrome c release and subsequent cell death .

Metabolic Effects: Research in obese primates demonstrates that Adipotide treatment leads to dose-dependent body weight reduction, decreased body mass index and abdominal circumference, and marked improvements in insulin resistance .

Research Applications:

• Obesity Research Models: Investigating targeted adipose tissue reduction

• Metabolic Studies: Examining insulin sensitivity and glucose regulation

• Adipose Tissue Biology: Exploring vascular-targeting approaches to fat reduction

• Type II Diabetes Research: Studying rapid metabolic improvements

Research Parameters

All dosages are for in-vitro research use only and are not intended for human consumption.

Primate Study Reference :

• Dose Range: 0.10, 0.25, 0.43, and 0.75 mg/kg 

• Administration: Daily subcutaneous injection

• Study Duration: 28-day treatment cycle 

• Observed Weight Loss: 7-15% body weight reduction in obese monkeys 

• Fat Reduction: 38% reduction in total body fat, 27% reduction in abdominal fat 

Storage:

• Store lyophilized powder at -20°C

• Protect from light and moisture